GOAL
To provide clinicians with the latest scientific data on diabetic retinopathy as well as practical strategies for its prevention, detection and treatment.

TARGET AUDIENCE
This activity is designed for primary care physicians, endocrinologists, diabetes educators and all clinicians involved in the care of patients with diabetes. There are no prerequisites.

LEARNING OBJECTIVES
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, participants should be able to:

• Describe the diagnosis, classification and manifestations of diabetic retinopathy (DR) in general and diabetic macular edema (DME) in particular
• Evaluate currently available and developing therapies for DR
• Establish the role of the diabetes specialist in the prevention, detection and treatment  of DR, both through direct patient contact and through interaction with other  healthcare providers

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

The estimated time to complete this educational activity: 2.0 hours.

Release date: August ___, 2006. Expiration date: August____, 2008.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.